PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2022; 11(04): 287-292
DOI: 10.1055/s-0042-1755467
Original Article
Bone and Soft Tissue Cancer

Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience

Metin Demir 
1   Department of Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
,
Denizcan Güven 
1   Department of Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
,
Burak Yasin Aktaş 
1   Department of Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
,
Gürkan Güner 
1   Department of Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
,
Oktay Halit Aktepe 
1   Department of Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
,
Hakan Taban 
1   Department of Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
,
Yusuf Karakaş 
1   Department of Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
,
Sadettin Kılıçkap 
1   Department of Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
,
Ayşe Kars 
1   Department of Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
,
Alev Türker 
1   Department of Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
,
Ömer Dizdar 
1   Department of Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
› Author Affiliations
Funding None.
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

Objective Liposarcomas are relatively rare tumors. Prognostic and predictive factors and treatment options are limited. We herein presented our 10-year experience with liposarcomas.

Materials and Methods Adult patients with liposarcoma treated between 2005 and 2015 in our center were included. Demographic and clinicopathologic features of patients were retrieved from patient files.

Statistical Analyses Outcomes in terms of disease-free survival (DFS) and overall survival (OS) were assessed along with potential prognostic factors using Kaplan–Meier analyses.

Results A total of 88 patients were included. The median age was 52. Rates of well-differentiated (WDLS), dedifferentiated (DDLS), myxoid (MLS), and pleomorphic liposarcomas (PLS) were 42, 9.1, 37.5, and 4.5%, respectively. Only 10% of patients had high-grade tumors and 93% had localized disease. Ninety-six percent of patients (n = 84) underwent surgery. Adjuvant chemotherapy was delivered to 16 patients. The most common regimen was ifosfamide–doxorubicin. Recurrences were observed in 30 patients, 21 had local, and 9 had distant metastasis. Five-year DFS of patients with the localized disease was 68%. All patients with PLS had relapses and those had the highest distant relapse rates among all subtypes. Multivariate analysis showed T stage and grade were associated with DFS. Five-year OS of the entire population was 68%. Five-year OS was 79, 76, 50, and 0% in WDLS, MLS, DDLS, and PLS, respectively (p = 0.002).

Conclusion Management of liposarcomas is still challenging. Surgery is the mainstay of treatment. Novel effective therapies are needed, particularly in advanced disease settings.

Keywords

liposarcoma - histologic subtypes - prognosis - surgery - Sarculator


Publication History

Article published online:
14 November 2022

© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Brennan, MF, Antonescu CR, Maki RG. Management of soft tissue sarcoma. New York: Springer; 2013
    Search in Google Scholar
  • 2 Bock S, Hoffmann DG, Jiang Y, Chen H, Ilyasova D. Increasing incidence of liposarcoma: a population-based study of national surveillance databases, 2001-2016. Int J Environ Res Public Health 2020; 17 (08) E2710
    CrossrefPubMedSearch in Google Scholar
  • 3 Gronchi A, Strauss DC, Miceli R. et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working group. Ann Surg 2016; 263 (05) 1002-1009
    CrossrefPubMedSearch in Google Scholar
  • 4 Chowdhry V, Goldberg S, DeLaney TF. et al. Myxoid liposarcoma: treatment outcomes from chemotherapy and radiation therapy. Sarcoma 2018; 2018: 8029157
    CrossrefPubMedSearch in Google Scholar
  • 5 Katz D, Boonsirikamchai P, Choi H. et al. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. Clin Sarcoma Res 2012; 2 (01) 2
    CrossrefPubMedSearch in Google Scholar
  • 6 Peterson JJ, Kransdorf MJ, Bancroft LW, O'Connor MI. Malignant fatty tumors: classification, clinical course, imaging appearance and treatment. Skeletal Radiol 2003; 32 (09) 493-503
    CrossrefPubMedSearch in Google Scholar
  • 7 Salduz A, Alpan B, Valiyev N. et al. Neoadjuvant radiotherapy for myxoid liposarcomas: oncologic outcomes and histopathologic correlations. Acta Orthop Traumatol Turc 2017; 51 (05) 355-361
    CrossrefPubMedSearch in Google Scholar
  • 8 Ghadimi MP, Liu P, Peng T. et al. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer 2011; 117 (23) 5359-5369
    CrossrefPubMedSearch in Google Scholar
  • 9 Hornick JL, Bosenberg MW, Mentzel T, McMenamin ME, Oliveira AM, Fletcher CD. Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases. Am J Surg Pathol 2004; 28 (10) 1257-1267
    CrossrefPubMedSearch in Google Scholar
  • 10 Amer KM, Congiusta DV, Thomson JE. et al. Epidemiology and survival of liposarcoma and its subtypes: a dual database analysis. J Clin Orthop Trauma 2020; 11 (Suppl 4): S479-S484
    CrossrefPubMedSearch in Google Scholar
  • 11 Bonvalot S, Rivoire M, Castaing M. et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol 2009; 27 (01) 31-37
    CrossrefPubMedSearch in Google Scholar
  • 12 Gronchi A, Casali PG, Mariani L. et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol 2005; 23 (01) 96-104
    CrossrefPubMedSearch in Google Scholar
  • 13 Gingrich AA, Bateni SB, Monjazeb AM. et al. Neoadjuvant radiotherapy is associated with R0 resection and improved survival for patients with extremity soft tissue sarcoma undergoing surgery: a National Cancer Database Analysis. Ann Surg Oncol 2017; 24 (11) 3252-3263
    CrossrefPubMedSearch in Google Scholar
  • 14 Moreau LC, Turcotte R, Ferguson P. et al; Canadian Orthopaedic Oncology Society (CANOOS). Myxoid cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases. Ann Surg Oncol 2012; 19 (04) 1081-1088
    CrossrefPubMedSearch in Google Scholar
  • 15 Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997; 350 (9092): 1647-1654
    CrossrefPubMedSearch in Google Scholar
  • 16 Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113 (03) 573-581
    CrossrefPubMedSearch in Google Scholar
  • 17 Gronchi A, Ferrari S, Quagliuolo V. et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 2017; 18 (06) 812-822
    CrossrefPubMedSearch in Google Scholar
  • 18 Gronchi A, Palmerini E, Quagliuolo V. et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol 2020; 38 (19) 2178-2186
    CrossrefPubMedSearch in Google Scholar
  • 19 Bonvalot S, Gronchi A, Le Péchoux C. et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020; 21 (10) 1366-1377
    CrossrefPubMedSearch in Google Scholar
  • 20 Billingsley KG, Burt ME, Jara E. et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg 1999; 229 (05) 602-610 , discussion 610–612
    Search in Google Scholar
  • 21 Chudgar NP, Brennan MF, Munhoz RR. et al. Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. J Thorac Cardiovasc Surg 2017; 154 (01) 319-330.e1
    CrossrefPubMedSearch in Google Scholar
  • 22 Smolle MA, Leithner A, Bernhardt GA. Abdominal metastases of primary extremity soft tissue sarcoma: a systematic review. World J Clin Oncol 2020; 11 (02) 74-82
    CrossrefPubMedSearch in Google Scholar
  • 23 Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005; 41 (18) 2853-2860
    CrossrefPubMedSearch in Google Scholar
  • 24 Demetri GD, von Mehren M, Jones RL. et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016; 34 (08) 786-793
    CrossrefPubMedSearch in Google Scholar
  • 25 Schöffski P, Chawla S, Maki RG. et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016; 387 (10028): 1629-1637
    CrossrefPubMedSearch in Google Scholar
  • 26 Langmans C, Cornillie J, van Cann T. et al. Retrospective analysis of patients with advanced liposarcoma in a tertiary referral center. Oncol Res Treat 2019; 42 (7-8): 396-404
    CrossrefPubMedSearch in Google Scholar
  • 27 Ray-Coquard I, Blay JY, Italiano A. et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012; 13 (11) 1133-1140
    CrossrefPubMedSearch in Google Scholar
  • 28 Roy S, Laroche-Clary A, Verbeke S, Derieppe MA, Italiano A. MDM2 antagonists induce a paradoxical activation of Erk1/2 through a P53-dependent mechanism in dedifferentiated liposarcomas: implications for combinatorial strategies. Cancers (Basel) 2020; 12 (08) E2253
    CrossrefPubMedSearch in Google Scholar
  • 29 Dickson MA, Schwartz GK, Keohan ML. et al. Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol 2016; 2 (07) 937-940
    CrossrefPubMedSearch in Google Scholar
  • 30 Tawbi HA, Burgess M, Bolejack V. et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017; 18 (11) 1493-1501
    CrossrefPubMedSearch in Google Scholar
  • 31 Sleijfer S, Ray-Coquard I, Papai Z. et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27 (19) 3126-3132
    CrossrefPubMedSearch in Google Scholar